Showing results (291-300 of 339) with videos related to

Sort By:
Pageof 34
Vaccine|January 7, 2009
Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of ageScott A Halperin, Bruce Tapiero, Francisco Diaz-Mitoma, et al.
Vaccine|September 4, 2023
Factors associated with intention for revaccination among patients with adverse events following immunizationCaroline E Muñoz, Anne Pham-Huy, Jeffrey M Pernica, et al.
Lancet Regional Health. Americas|December 1, 2025
Healthcare costs and resource utilization for acute respiratory syncytial virus pediatric hospitalizations in Canada: a population-based studyNirma Khatri Vadlamudi, Kyle Gomes, Ethan Chow, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 16, 2005
Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteersShelly A McNeil, Scott A Halperin, Joanne M Langley, et al.
Human Vaccines & Immunotherapeutics|January 8, 2025
Considering the impact of vaccine communication in the COVID-19 pandemic among adults in Canada: A qualitative study of lessons learned for future vaccine campaignsJeanna Parsons Leigh, Stephana Julia Moss, Jade MacDonald, et al.
CMAJ Open|April 14, 2021
Obstetric and perinatal health outcomes after pertussis vaccination during pregnancy in Ontario, Canada: a retrospective cohort studyRomina Fakhraei, Natasha Crowcroft, Shelly Bolotin, et al.
Journal of Clinical Epidemiology|November 26, 2025
The Risk of Bias in Vaccine Effectiveness (RoB-VE) project: introduction to a methodological initiative to improve risk-of-bias assessment and reporting in vaccine effectiveness researchCassandra Laurie, Pablo Alonso Coello, Ivan D Florez, et al.
Vaccine|February 14, 2012
Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of ageScott A Halperin, Brian Ward, Curtis Cooper, et al.
CMAJ Open|February 3, 2023
Trends and characteristics of Tdap vaccination during pregnancy in Ontario, Canada: a retrospective cohort studyRomina Fakhraei, Stephen G Fung, William Petrcich, et al.
Vaccine|August 12, 2025
Knowledge gaps and research priorities regarding vaccination in pregnancy: A Canadian perspective from the prevention of infections in the maternal-infant dyad (PRIMED) consortiumOlivia F Hunter, Elisabeth McClymont, Oscar Lau, et al.
Pageof 34